GSK R&D chief Hal Barron has turned to another Bay Area biotech for his latest oncology drug development pact, which could total billions for a preclinical deal that starts with $120 million in cash. And this one speaks directly to one of his favorite topics: synthetic lethality. Barron is partnering
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met…
Endpoints News reviews 2024’s biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA’s setback in misinformation fight.
Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for an experimental sickle cell therapy, and will halt development on…
The Endpoints 100 is our semi-regular survey of biotech and pharma executives.
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures’ three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years…
We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and…
Novartis is acquiring Kate Therapeutics for $1.1 billion, focusing on gene therapy and neuroscience. CEO Vas Narasimhan and CFO Harry Kirsch indicate future M&A deals…
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a…
Sage’s final hope to turn its business around has failed, leaving the future of the once high-flying company and its postpartum depression drug uncertain.
We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and…
